Nanobiotix S. A. is a late-stage clinical biotechnology company specializing in the development of physics-based nanotherapeutics designed to transform treatment outcomes for patients with cancer and other serious diseases. Founded in 2003 as a spin-off from the State University of New York at Buffalo, the company leverages nanotechnology to create first-in-class therapies that enhance the efficacy of existing treatments while minimizing damage to healthy tissues. Nanobiotix’s core focus lies in oncology, where its lead product candidate, JNJ-1900 (NBTXR3), aims to revolutionize radiotherapy by amplifying tumor destruction without increasing radiation doses to surrounding healthy cells. The company operates with a multidisciplinary approach, combining expertise in physics, biology, and medicine to pioneer innovative solutions in nanomedicine.

Nanobiotix generates revenue primarily through strategic collaborations, licensing agreements, and milestone payments tied to the development and commercialization of its nanotherapeutic platforms. Its most advanced asset, JNJ-1900 (NBTXR3), is the subject of a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, which includes upfront payments, development and regulatory milestones, and tiered royalties on future net sales. The company also receives funding through research collaborations, such as its partnership with The University of Texas MD Anderson Cancer Center, and may derive additional revenue from its preclinical platforms, Curadigm and OOcuity, as they advance toward clinical development. While Nanobiotix has not yet commercialized any products, its revenue model is structured around long-term partnerships and the successful progression of its pipeline through clinical trials.

The company operates through the following segments:

• Nanoradioenhancer Platform: This segment focuses on the development of JNJ-1900 (NBTXR3), a hafnium oxide-based nanoparticle designed to enhance the tumor-killing effects of radiotherapy. Administered via a single intratumoral injection, JNJ-1900 (NBTXR3) amplifies energy absorption within cancer cells when activated by radiation, increasing local tumor control while sparing healthy tissues. The platform is being evaluated across multiple solid tumor indications, including head and neck, lung, pancreatic, esophageal, liver, prostate, and soft tissue sarcoma cancers. Positive clinical data has been observed in several trials, and the asset is currently in Phase 3 development for locally advanced head and neck squamous cell carcinoma in elderly patients ineligible for platinum-based chemotherapy.

• Nanoprimer Platform (Curadigm): This preclinical segment aims to address a universal challenge in modern medicine: the hepatic clearance and toxicity of intravenously administered therapeutics. The Curadigm Nanoprimer consists of engineered lipid-based nanoparticles that transiently occupy liver pathways responsible for drug clearance, enabling higher concentrations of subsequently administered drugs to reach target tissues. This technology has potential applications across RNA vaccines, gene therapies, oncolytic viruses, and nanomedicines, with the goal of improving efficacy or reducing toxicity. The platform is being explored for both internal development and external collaborations.

• Neurological Disease Platform (OOcuity): This early-stage segment investigates the use of nanoparticles to modulate neuronal networks in the central and peripheral nervous systems. The research focuses on developing first-in-class products that interact with electrical signals in the brain to alleviate symptoms of neurological diseases such as Parkinson’s, Alzheimer’s, dementia, and neuropathic pain. By acting as conductors, insulators, or semiconductors, OOcuity nanoparticles aim to synchronize or regulate disrupted neuronal activity, offering a novel approach to treating conditions driven by electrical signal asynchronicity.

Nanobiotix is positioned as a pioneer in the emerging field of physics-based nanotherapeutics, distinguishing itself from traditional biopharmaceutical companies that focus on biologically targeted therapies. Its competitive advantage lies in the universal applicability of its platforms, particularly JNJ-1900 (NBTXR3), which is designed to integrate seamlessly into existing radiotherapy protocols without requiring additional equipment or significant changes to clinical workflows. The company’s strategic collaborations with industry leaders, such as Janssen and MD Anderson, further strengthen its market position by providing financial resources, regulatory expertise, and global development capabilities. Key competitors in the radiotherapy enhancement space include MagForce AG, NH TherAguix, Nanospectra Biosciences, RiMO Therapeutics, and Coordination Pharmaceuticals, all of which are developing technologies to improve tumor sensitivity to radiation or protect healthy tissues. However, Nanobiotix’s broad intellectual property portfolio, encompassing over 500 issued or pending patents across more than 30 families, provides a robust foundation for long-term differentiation. The company’s focus on addressing large, underserved patient populations, such as those with locally advanced cancers or neurological disorders, positions it to capture significant market opportunities upon successful commercialization.

Nanobiotix’s customer base primarily consists of healthcare providers, including hospitals, cancer treatment centers, and academic medical institutions that administer radiotherapy and other oncology treatments. Its lead product candidate, JNJ-1900 (NBTXR3), is being developed in collaboration with prominent partners such as Janssen Pharmaceutica NV and The University of Texas MD Anderson Cancer Center, which are actively involved in clinical trials and potential future commercialization. The company’s therapies are designed to serve patients with solid tumors, particularly those receiving radiotherapy as part of their treatment regimen. As Nanobiotix advances its preclinical platforms, its addressable market may expand to include patients with neurological diseases and those receiving innovative systemic therapies, such as RNA vaccines or gene therapies. The ultimate end-users of its products will be cancer patients and individuals with debilitating neurological conditions, with adoption driven by the medical community’s need for safer and more effective treatment options.